Myelin Repair Foundation
Latest From Myelin Repair Foundation
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2015.
A new high-throughput assay developed at the University of California, San Francisco has already identified a generic over-the-counter drug that promotes remyelination. A clinical trial is soon to follow, only the second for myelin repair in multiple sclerosis.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
For decades drug discovery meant testing new compounds in cells and animals without knowing how or why they might work. A shift to reductionist, target-based discovery has done little to nothing to bring more drugs to market. Proponents say it’s time for more phenotypic inquiry early in the drug discovery process, bolstered when possible by better tools and technology.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.